pharmaphorum May 3, 2024
Walgreens’ plans to disrupt the clinical trials sector have taken a step forward with a high-profile partnership with Boehringer Ingelheim.
The German pharma group will tap into Walgreens’ network of community pharmacies to recruit patients for a large-scale trial involving people who are overweight, living with obesity, and/or have type 2 diabetes.
Media reports suggest that the study will involve Boehringer’s survodutide, a dual agonist of GLP-1 and glucagon, co-developed with Zealand Pharma, that is in a phase 3 programme in obesity and recently generated positive phase 2 data in metabolic dysfunction-associated steatohepatitis (MASH), a liver disease linked to overweight and diabetes.
Walgreens launched its clinical research business in 2022, aiming to tap into its reserves of patient data as...
Today's Sponsors
Today's Sponsor